Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2023 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
April 04, 2023 03:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals kondigt overname aan van Xinvento B.V. en portfolio van Investigational Therapeutics

– Bedrijf dat zich richt op zeldzame ziekten bezig met preklinische ontwikkeling voor congenitaal hyperinsulinisme – – De overname is zeer strategisch, sluit aan bij de huidige focus van Rhythm op...
March 27, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

- Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food – - Company also announces publication...
March 06, 2023 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
March 01, 2023 07:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

-- IMCIVREE® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval -- -- IMCIVREE now available in eight ex-U.S. markets;...
February 27, 2023 08:45 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new...
February 21, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
February 08, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...
January 23, 2023 08:00 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

- Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide - - Analysis published in Orphanet...
January 05, 2023 16:01 ET | Source: Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Announces New Employment Inducement Grants

BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families...